Publications by authors named "H Kalofonos"
Background: Testicular germ cell tumors (TGCTs) exhibit diverse biological and pathological features and are divided in two main types, seminomas and nonseminomatous germ cell tumors (NSGCTs). CD44 is a cell surface receptor, which is highly expressed in malignancies and is implicated in tumorigenesis affecting cell-matrix interactions and cell signaling.
Methods And Results: Here, we examined the expression of CD44 in tumor cell lines and in patients' material.
Objective: To define the incidence and risk factors for developing chemotherapy-induced neuropathic pain (CINP).
Methods: Retrospective, file-based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy-induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI-NRS and Douleur Neuropathique-4 questionnaire.
Article Synopsis
- Breast cancer is a major health issue for women and sometimes treatments work less effectively due to resistance.
- Researchers created special cell lines that are resistant to common treatments like fulvestrant and tamoxifen to study why this happens.
- These resistant cells can still grow even without estrogen and show increased survival abilities, which makes finding better treatments even more important.
Article Synopsis
- This study investigates how R&P denervation affects tumor growth and survival in rats with aggressive breast tumors.
- A unique microsurgical technique is used to disconnect nerve fibers linked to the tumor, aiming to create a therapeutic time window by delaying the return of nerve activity.
- Results show that rats with the denervated tumors experienced primary tumor regression and improved survival rates, compared to those with intact neurovascular connections, suggesting a potential new treatment for cancer.
Background: In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free following 1L platinum-based chemotherapy, leading to regulatory approval in various countries.
Objective: To analyze clinically relevant subgroups from JAVELIN Bladder 100.
Design, Setting, And Participants: Patients with unresectable locally advanced or metastatic UC without progression on 1L gemcitabine + cisplatin or carboplatin were randomized to receive avelumab + BSC (n = 350) or BSC alone (n = 350).